New Blood issue out now featuring:.NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma

New Blood issue out now featuring:.Age shapes the immunogenetic fingerprint of ALL

NTRK1-rearranged histiocytosis often presents as 1 or multiple cutaneous xanthogranulomas but may rarely involve extracutaneous tissues. #clinicaltrialsandobservations #myeloidneoplasia

📣Join the second look program!.#BloodPortfolio

A high monoblasts/CD45+ proportion predicts poor response and reduced survival in newly diagnosed patients with AML receiving Ven-Aza. #clinicaltrialsandobservations #myeloidneoplasia

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice #redcellsironanderythropoiesis

LS arises rapidly after immune-targeted therapy, highlighting the importance of enhanced methods of detection and treatment. #immunobiologyandimmunotherapy #lymphoidneoplasia

Prophylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy. #clinicaltrialsandobservations #immunobiologyandimmunotherapy

Clinicians should recognize that combining these scores may obscure risk stratification and impede personalized treatment strategies. #clinicaltrialsandobservations #thrombosisandhemostasis

B-lineage transcription factor EBF1 directly regulates the expression of CD22 and modulates ALL sensitivity to InO. #lymphoidneoplasia

RBCs suspended in platelet-depleted plasma undergo aggregation within a thrombin-induced clot and cause platelet-independent clot shrinkage. #redcellsironanderythropoiesis #thrombosisandhemostasis

Postimmunotherapy lineage switch: where to from here? #immunobiologyandimmunotherapy

Ven causes more infections and neutropenia but fewer cardiovascular issues than BTKi, whereas serious infections (grade 3-4) are similar. #lymphoidneoplasia

Adenovirus holds the platelet in flow #thrombosisandhemostasis.

Statin use is significantly associated with overall, cancer-specific, and progression-free survival in CLL/SLL patients treated with contemporary regimens, including ibrutinib. #healthservicesandoutcomes #lymphoidneoplasia

Targeting B-cell identity: how EBF1 modulates InO response #lymphoidneoplasia

Lymphoma B cells trigger transcriptional reprogramming and deregulation of ECM organization in BM stromal cells. #lymphoidneoplasia

MPL is required for JAK2 V617F–dependent expansion of hematopoietic stem cells but not of early hematopoietic progenitors. #myeloidneoplasia #hematopoiesisandstemcells #plateletsandthrombopoiesis

We found that the small molecule AS1842856, previously considered a specific inhibitor of FOXO1, also directly inhibits GSK3. #lymphoidneoplasia

Immunogenicity of red blood cell antigens is related to protein structure at amino acid substitution sites that create the antigens. #immunobiologyandimmunotherapy #transfusionmedicine

Prophylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy.